DK1310249T3 - Anvendelse af polyumættede fedtsyrer til primær forebyggelse af större hjerte-kar anfald - Google Patents

Anvendelse af polyumættede fedtsyrer til primær forebyggelse af större hjerte-kar anfald

Info

Publication number: DK1310249T3
Authority: DK; Denmark
Prior art keywords: fatty acids; polyunsaturated fatty; seizures; primary prevention; major cardiovascular
Prior art date: 2001-11-12

Application number

DK02023126T

Other languages

English (en)

Inventor

Hajime Shibuya

Original Assignee

Pro Aparts Investimentos E Con

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-12

Filing date

2002-10-15

Publication date

2006-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1310249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-10-15 Application filed by Pro Aparts Investimentos E Con filed Critical Pro Aparts Investimentos E Con

2006-09-25 Application granted granted Critical

2006-09-25 Publication of DK1310249T3 publication Critical patent/DK1310249T3/da

Links

235000020777 polyunsaturated fatty acids Nutrition 0.000 title abstract 2
230000009862 primary prevention Effects 0.000 title abstract 2
206010010904 Convulsion Diseases 0.000 title 1
230000002526 effect on cardiovascular system Effects 0.000 title 1
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 3
235000020669 docosahexaenoic acid Nutrition 0.000 abstract 2
235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
206010061216 Infarction Diseases 0.000 abstract 1
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
230000007211 cardiovascular event Effects 0.000 abstract 1
229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
230000007574 infarction Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK02023126T 2001-11-12 2002-10-15 Anvendelse af polyumættede fedtsyrer til primær forebyggelse af större hjerte-kar anfald DK1310249T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001MI002384A ITMI20012384A1 (it)	2001-11-12	2001-11-12	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori

Publications (1)

Publication Number	Publication Date
DK1310249T3 true DK1310249T3 (da)	2006-09-25

Family

ID=11448595

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02023126T DK1310249T3 (da)	2001-11-12	2002-10-15	Anvendelse af polyumættede fedtsyrer til primær forebyggelse af större hjerte-kar anfald

Country Status (10)

Country	Link
US (4)	US20030100610A1 (da)
EP (1)	EP1310249B1 (da)
JP (1)	JP4731789B2 (da)
AT (1)	ATE331510T1 (da)
CY (1)	CY1105119T1 (da)
DE (1)	DE60212786T2 (da)
DK (1)	DK1310249T3 (da)
ES (1)	ES2262741T3 (da)
IT (1)	ITMI20012384A1 (da)
PT (1)	PT1310249E (da)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
ITMI20012384A1 (it) *	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
GB0403247D0 (en)	2004-02-13	2004-03-17	Tillotts Pharma Ag	A pharmaceutical composition
US8324276B2 (en)	2005-01-24	2012-12-04	Pronova Biopharma Norge As	Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
KR101255650B1 (ko) *	2005-05-04	2013-04-16	프로노바 바이오파마 너지 에이에스	새로운 ｄｈａ 유도체 및 약제로서의 용도
JP5337479B2 (ja) *	2005-05-04	2013-11-06	プロノヴァ・バイオファーマ・ノルゲ・アーエス	新規化合物
RU2441061C2 (ru) *	2005-05-04	2012-01-27	Пронова Биофарма Норге Эс.	Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
CN101213281B (zh) *	2005-05-04	2013-03-13	普罗诺瓦生物医药挪威公司	新的dha衍生物及其作为药物的用途
JP5134916B2 (ja) *	2005-07-08	2013-01-30	持田製薬株式会社	心血管イベント発症予防用組成物
CN101217952B (zh)	2005-07-08	2014-03-12	持田制药株式会社	用于预防心血管事件发病的组合物
US20070104779A1 (en) *	2005-11-07	2007-05-10	Rongen Roelof M	Treatment with omega-3 fatty acids and products thereof
EP1968567B1 (en) *	2005-12-20	2014-06-18	Cenestra, Llc	Omega 3 fatty acid formulations
ES2277557B1 (es) *	2005-12-21	2008-07-01	Proyecto Empresarial Brudy, S.L.	Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US8399516B2 (en)	2006-11-01	2013-03-19	Pronova Biopharma Norge As	Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
WO2008142482A2 (en)	2006-11-01	2008-11-27	Pronova Biopharma Norge As	Omega-3 lipid compounds
US20080125490A1 (en) *	2006-11-03	2008-05-29	My Svensson	Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
JP2010509204A (ja) *	2006-11-03	2010-03-25	プロノヴァバイオファーマノルゲアーエス	脂肪酸アルコール
US20080306154A1 (en) *	2006-11-03	2008-12-11	My Svensson	Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US8343753B2 (en)	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US8592439B2 (en)	2008-08-07	2013-11-26	Spa Societa Prodotti Antibiotici S.P.A.	Long-term treatment of symptomatic heart failure
WO2010018856A1 (ja) *	2008-08-13	2010-02-18	持田製薬株式会社	カンナビノイド受容体関連疾患の予防／改善または治療剤
EP3187182B1 (en)	2008-09-02	2021-03-03	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
RU2505292C2 (ru)	2009-02-10	2014-01-27	Амарин Фармасьютикалз Айрлэнд Лимитед	Способы лечения гипертриглицеридемии
AU2014203034B2 (en) *	2009-04-29	2016-09-15	Amarin Pharmaceuticals Ireland Limited	Stable pharmaceutical composition and methods of using same
CN107233337A (zh)	2009-04-29	2017-10-10	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
MX377553B (es)	2009-04-29	2025-03-10	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt) *	2009-06-15	2016-09-13	Amarin Pharma Inc	uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en)	2009-09-23	2014-05-30	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP3335713B1 (en) *	2009-10-29	2022-08-31	Acasti Pharma, Inc.	Concentrated therapeutic phospholipid compositions
CA3066588C (en) *	2010-03-04	2022-03-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating and/or preventing cardiovascular disease
ITMI20100961A1 (it) *	2010-05-27	2011-11-28	Erredue Spa	Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
US20140039053A1 (en) *	2011-02-07	2014-02-06	Mochida Pharmaceutical Co., Ltd.	Therapeutic agent for diastolic congestive heart failure
JP2014506891A (ja)	2011-02-16	2014-03-20	ピヴォタルセラピューティクスインコーポレイテッド	心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
US8951514B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
EP2675446A1 (en)	2011-02-16	2013-12-25	Pivotal Therapeutics, Inc.	Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
US20120302639A1 (en)	2011-02-16	2012-11-29	Pivotal Therapeutics Inc.	Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US9119826B2 (en)	2011-02-16	2015-09-01	Pivotal Therapeutics, Inc.	Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en)	2011-02-16	2015-02-10	Pivotal Therapeutics Inc.	Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en)	2011-02-16	2014-05-06	Pivotal Therapeutics Inc.	Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US20140191573A1 (en) *	2011-09-24	2014-07-10	Kool Koncepts Limited	Energy management system
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
EP2800469B1 (en)	2012-01-06	2021-08-25	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
CN107050457A (zh)	2012-01-06	2017-08-18	翁特拉制药公司	游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
US9603826B2 (en)	2012-06-29	2017-03-28	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9382187B2 (en)	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US8765811B2 (en)	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
WO2014011895A2 (en) *	2012-07-11	2014-01-16	Thetis Pharmaceuticals Llc	High solubility acid salts, intravenous dosage forms, nutrition supplementation and methods of use thereof
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015171516A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
CN107074884A (zh)	2014-06-18	2017-08-18	西蒂斯制药有限责任公司	活性剂的矿物质氨基酸复合物
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
KR102437682B1 (ko)	2016-06-03	2022-08-29	테티스 파마수티컬스 엘엘씨	특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
US10966951B2 (en)	2017-05-19	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
WO2019008101A1 (en)	2017-07-06	2019-01-10	Evonik Technochemie Gmbh	ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
KR102628351B1 (ko)	2017-08-15	2024-01-25	에보니크 오퍼레이션즈 게엠베하	오메가-3 지방산 아미노산 염의 높은 활성 성분 함량을 갖는 정제
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr)	2018-09-24	2020-09-02	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US20220287345A1 (en)	2019-08-08	2022-09-15	Evonik Operations Gmbh	Solubility enhancement of poorly soluble actives
KR102977459B1 (ko)	2019-08-08	2026-06-16	에보니크 오퍼레이션즈 게엠베하	다중불포화 지방산 염의 제조를 위한 다운스트림 공정
CA3160676A1 (en)	2019-11-12	2021-05-20	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
WO2021197971A1 (en) *	2020-04-01	2021-10-07	Evonik Operations Gmbh	Preparation for use as antioxidant
EP4125437A1 (en) *	2020-04-01	2023-02-08	Evonik Operations GmbH	Preparation for use as vasorelaxant
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure
CN115820268B (zh) *	2022-11-26	2025-06-20	成都惠恩精细化工有限责任公司	鱼油基氨基酸表面活性剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4805062A (en)	1986-10-15	1989-02-14	Hitachi, Ltd.	DC circuit breaker and method of commutation thereof
IT1205043B (it) *	1987-05-28	1989-03-10	Innova Di Ridolfi Flora & C S	Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US4918104A (en) *	1987-06-16	1990-04-17	Weiss Howard S	Method and composition for increasing the concentration of omega-3 polyunsaturated fatty acids in poultry and poultry eggs and poultry and eggs resulting therefrom
GB2218984B (en)	1988-05-27	1992-09-23	Renafield Limited	Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH0225447A (ja)	1988-07-13	1990-01-26	Nippon Oil & Fats Co Ltd	高度不飽和脂肪酸類の製造方法
GB8819110D0 (en) *	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
JP2893866B2 (ja) *	1990-05-25	1999-05-24	日本油脂株式会社	抗不整脈薬
GB9125602D0 (en) *	1991-12-02	1992-01-29	Efamol Holdings	Method of preventing reocclusion of arteries
CN1082909A (zh)	1993-01-03	1994-03-02	潘玉珍	精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH06263634A (ja) *	1993-03-10	1994-09-20	Sagami Chem Res Center	カルシウム拮抗薬
US5760081A (en) *	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
IT1274734B (it) *	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5541225A (en) *	1994-10-11	1996-07-30	The General Hospital Corporation	α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia
NL9401743A (nl) *	1994-10-20	1996-06-03	Prospa Bv	Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
MY118354A (en) *	1995-05-01	2004-10-30	Scarista Ltd	1,3-propane diol derivatives as bioactive compounds
WO1997019683A1 (en) *	1995-11-28	1997-06-05	B. Braun Melsungen Ag	Hydrolysis-optimized lipid emulsions and use thereof
IT1277953B1 (it) *	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
JPH10139664A (ja) *	1996-11-12	1998-05-26	Sagami Chem Res Center	抗不整脈薬
JPH11239464A (ja) *	1997-06-16	1999-09-07	Nippon Suisan Kaisha Ltd	運動時の危険因子除去能を有する組成物
US6284268B1 (en) *	1997-12-10	2001-09-04	Cyclosporine Therapeutics Limited	Pharmaceutical compositions containing an omega-3 fatty acid oil
DE19855426A1 (de) *	1998-12-02	2000-06-08	Wolfgang Langhoff	Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
IT1308613B1 (it)	1999-02-17	2002-01-09	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
AUPQ480399A0 (en)	1999-12-22	2000-02-03	Commonwealth Scientific And Industrial Research Organisation	Unsaturated fatty acids and their uses in therapy
IL151299A0 (en) *	2000-02-16	2003-04-10	Brigham & Womens Hospital	Aspirin-triggered lipid mediators
EP1157692B1 (en) *	2000-05-22	2005-10-05	Pro Aparts - Investimentos E Consultoria Lda	Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
JP4337273B2 (ja) *	2001-04-20	2009-09-30	日本水産株式会社	基礎代謝増進剤
EP1279400A1 (en) *	2001-07-25	2003-01-29	Target Hit sa	Modifying the fatty acid composition of cell membranes of organs and tissues
AU784852B2 (en) *	2001-08-10	2006-07-06	Mars, Incorporated	Canine support diet
ITMI20012384A1 (it) *	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030144219A1 (en) *	2001-11-15	2003-07-31	Phinney Stephen Dodge	Formulations and methods for treatment or amelioration of inflammatory conditions
EP2099295A4 (en)	2006-11-22	2010-02-24	Reliant Pharmaceuticals Inc	PROPHYLAXIS AND TREATMENT OF AURICULAR FIBRILLATION WITH OMEGA-3 FATTY ACIDS

2001
- 2001-11-12 IT IT2001MI002384A patent/ITMI20012384A1/it unknown
2002
- 2002-10-15 PT PT02023126T patent/PT1310249E/pt unknown
- 2002-10-15 ES ES02023126T patent/ES2262741T3/es not_active Expired - Lifetime
- 2002-10-15 DK DK02023126T patent/DK1310249T3/da active
- 2002-10-15 AT AT02023126T patent/ATE331510T1/de active
- 2002-10-15 EP EP02023126A patent/EP1310249B1/en not_active Revoked
- 2002-10-15 DE DE60212786T patent/DE60212786T2/de not_active Expired - Lifetime
- 2002-10-25 JP JP2002310878A patent/JP4731789B2/ja not_active Expired - Fee Related
- 2002-10-28 US US10/281,208 patent/US20030100610A1/en not_active Abandoned
2004
- 2004-02-17 US US10/778,182 patent/US7553870B2/en not_active Expired - Lifetime
2006
- 2006-07-31 CY CY20061101067T patent/CY1105119T1/el unknown
2007
- 2007-11-19 US US11/984,485 patent/US7619002B2/en not_active Expired - Fee Related
2009
- 2009-09-29 US US12/568,997 patent/US8648061B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2003146874A (ja)	2003-05-21
US20080269331A1 (en)	2008-10-30
US20100016428A1 (en)	2010-01-21
US7619002B2 (en)	2009-11-17
DE60212786D1 (de)	2006-08-10
CY1105119T1 (el)	2009-11-04
JP4731789B2 (ja)	2011-07-27
ITMI20012384A1 (it)	2003-05-12
DE60212786T2 (de)	2007-06-28
US8648061B2 (en)	2014-02-11
EP1310249B1 (en)	2006-06-28
PT1310249E (pt)	2006-09-29
US20040162349A1 (en)	2004-08-19
US7553870B2 (en)	2009-06-30
ATE331510T1 (de)	2006-07-15
ES2262741T3 (es)	2006-12-01
EP1310249A1 (en)	2003-05-14
US20030100610A1 (en)	2003-05-29

Publication	Publication Date	Title
DE60212786D1 (de)	2006-08-10	Verwendung von polyungesättigten Fettsäuren zur primären Vorbeugung von kardiovaskulären Anfällen
NO20035281L (no)	2003-11-27	Koenzym Q og EPA eller andre essensielle fettsyrer
ATE221324T1 (de)	2002-08-15	Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
DK1152755T3 (da)	2002-07-22	Essentielle fedtsyrer til forebyggelse af cardiovaskulære tilfælde
ES2477584T3 (es)	2014-07-17	Esterificación de aceite marino catalizada por lipasa
DK1157692T3 (da)	2006-02-06	Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
EP1534261A4 (en)	2007-09-19	EPA AND DHA ENHANCED OMEGA-3 SUPPLEMENT FOR THE TREATMENT OF DRY EYE, MEIBOMIANITIS AND XEROSTOMY
IS5017A (is)	1999-03-30	Lyfjasamsetning sem inniheldur eikósapentaensýru og/eða stearidónsýru
KR940018091A (ko)	1994-08-16	불포화 지방산을 포함하는 처방
DK1135998T3 (da)	2003-12-08	Anvendelse af syntetiske triglycerider på basis af konjugeret linolsyre som antioxidant i levnedsmidler
EP0292846A3 (en)	1990-03-21	A process for the extraction of polyunsaturated fatty acid esters from fish oils and pharmaceutical and/or dietetic compositions containing said esters
WO1997039749A3 (en)	1997-12-04	Method for the prevention and treatment of cachexia and anorexia
BRPI0408006A (pt)	2006-02-14	uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos
EP0302482A3 (en)	1990-08-22	Free fatty acids for treatment or prophylaxis of rheumatoid arthritis
AU2003238240A1 (en)	2003-12-31	ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
DK0623019T3 (da)	2000-10-02	Medikamenter på basis af docosahexaensyre som midler mod blodpladeaggregation og mod cerebral mangel på essentielle fedtsyr
EP1698685A4 (en)	2008-12-03	FAT COMPOSITION
AU2441400A (en)	2000-08-29	Stabilized lipidic composition, method for the preparation thereof and nutritional product containing the same
PT804411E (pt)	2003-12-31	Analogos sinteticos de acidos gordos poli-insaturados
RU93049092A (ru)	1996-06-10	Лечение жирными кислотами
FR2843124B1 (fr)	2004-10-15	Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
NO20014341L (no)	2001-09-06	Opplösning av flerumettede fettsyrer og derivater derav ved dannelse av inklusjonssammensetninger med <gamma>-syklodekstrin ogbruk derav i farmasöytiske, kosmetiske eller matsammensetninger
DK0585027T3 (da)	1998-05-11	Anvendelse af fedtsyrer til behandling af abnorm vævsforkalkning
NZ304924A (en)	2000-05-26	hybridised triglycerides
TW360545B (en)	1999-06-11	Dermatologic preparation